Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03523377 · ClinicalTrials.gov registry record · NA

Overnight Fasting After Completion of Therapy: The OnFACT Study

A NA study of Childhood Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT03523377: Active NA study of Childhood Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03523377 is a NA study of Childhood Cancer Survivors that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants, below the 991-participant average among 6 other Childhood Cancer Survivors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03523377, a NA study of Childhood Cancer Survivors, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test whether regularly not eating for at least 14 hours overnight ("intermittent fasting") is feasible and can improve blood sugar.

Primary Outcome

Proportion of registered participants who successfully complete the 6-month intervention

Conditions Studied

Interventions

  • OTHER prolonged overnight fasting
  • OTHER usual care

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2018-04-27
Est. Completion 2026-04
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03523377 still lists

NCT03523377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 991-participant average among 6 other Childhood Cancer Survivors trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Childhood Cancer Survivors appearing as the primary indexed condition, and to 2 interventions - of which prolonged overnight fasting is the first listed.

NCT03523377 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03523377 about?

NCT03523377 is a clinical study titled "Overnight Fasting After Completion of Therapy: The OnFACT Study". The purpose of this study is to test whether regularly not eating for at least 14 hours overnight ("intermittent fasting") is feasible and can improve blood sugar.

What is the current status of trial NCT03523377?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2018-04-27. Estimated completion is 2026-04.

What conditions does trial NCT03523377 study?

This clinical trial studies the following conditions: Childhood Cancer Survivors.

What interventions are being tested in trial NCT03523377?

The interventions under investigation include: prolonged overnight fasting (OTHER), usual care (OTHER).

Who is sponsoring clinical trial NCT03523377?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03523377 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Childhood Cancer Survivors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03523377, the US trial registry maintained by the National Library of Medicine. NCT03523377 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.